LENZ (LENZ Therapeutics) Gross-Profit-to-Asset % : 0.00% (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is LENZ Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. LENZ Therapeutics's annualized Gross Profit for the quarter that ended in Sep. 2024 was $0.00 Mil. LENZ Therapeutics's average Total Assets over the quarter that ended in Sep. 2024 was $213.32 Mil. Therefore, LENZ Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 0.00%.

LENZ Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for LENZ Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENZ Therapeutics Gross-Profit-to-Asset % Chart

LENZ Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

45.95

LENZ Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of LENZ Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, LENZ Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LENZ Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LENZ Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where LENZ Therapeutics's Gross-Profit-to-Asset % falls into.

LENZ Therapeutics Gross-Profit-to-Asset % Calculation

LENZ Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (46.951	+	70.376)	/ 2 )
	=	0	/	58.6635
	=	0.00 %

LENZ Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	0	/	( (202.639	+	224.007)	/ 2 )
	=	0	/	213.323
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

LENZ Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of LENZ Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

LENZ Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LENZ Therapeutics Inc (NAS:LENZ) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

445 Marine View Avenue, STE No. 320, Del Mar, CA, USA, 92014

Website

https://www.lenz-tx.com

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.